Goldenseal

Hydrastis canadensis L. was published by Linnaeus in 1759, in the tenth edition of Systema Naturae (Kew’s Plants of the World Online). It belongs to Ranunculaceae, the buttercup family, although a US Forest Service review notes that several studies have suggested the genus deserves a family of its own. Kew gives its native range as southeastern Canada to the north-central and eastern United States: Ontario and 25 states from Vermont and Connecticut west to Minnesota and Iowa and south to Georgia, Alabama, Mississippi, and Arkansas. NatureServe places the core of the range in Indiana, Kentucky, Ohio, and West Virginia, around the Ohio River valley. King’s American Dispensatory (1898) calls the genus name, from Greek words linked to water, a misnomer based on the mistaken belief that the plant grew in bogs; it actually prefers rich, open woodland hillsides strewn with leaf mold. Common names recorded by King’s and the Forest Service include yellow root, orange root, yellow puccoon, eye root, eye balm, Indian paint, Indian dye, jaundice root, wild curcuma, and Indian turmeric. MSKCC warns that goldenseal is sometimes called turmeric root but should not be confused with turmeric (Curcuma longa).

Mature plants send up a single hairy stem up to about 12 inches (30 cm) tall, yellow below ground and purplish above, which forks into two palmate leaves, each with five to seven toothed lobes (US Forest Service). The leaves are only partly open at flowering and keep growing afterwards, reaching 3 to 12 inches across, one usually larger than the other. Young or weak plants produce one leaf and no flower. The single flower appears in April or May, is about half an inch across, and lasts only five or six days; its three small, petal-like sepals fall as it opens, so what you see is a tuft of white stamens around a cluster of small pistils. By midsummer the flower becomes a red, raspberry-like cluster of small fleshy fruits, each holding one or two shiny black seeds (King’s). Seeds that fall in late summer germinate the following spring, a seedling spends its second year with a single leaf, and plants usually first flower in their third or fourth year (Forest Service, citing Bowers 1891).

The medicinal part is the rhizome, a horizontal, knotty underground stem about half to three-quarters of an inch thick with many fibrous rootlets. Fresh, it is vivid yellow inside and out; it dries to a dull brown with a lemon-yellow break and loses about two-thirds of its weight in drying (King’s). The name goldenseal combines that color with the round scars that each year’s dead stem leaves on the rhizome, which reminded people of the imprint of a wax seal; King’s credits the Thomsonian botanical healers with introducing the name. Rhizomes mature after four to five years, then die back at one end as they grow at the other. Wild plants spread mostly by budding from rhizomes and rootlets, forming dense clonal patches. Goldenseal grows under a shady canopy of sugar maple, beech, red oak, basswood, or black walnut, alongside American ginseng, black cohosh, bloodroot, and mayapple, and it does not return to land that has been cleared or plowed (Forest Service). NatureServe found that 62% of Ohio populations had fewer than 200 stems.

King’s American Dispensatory described three alkaloids in the root: yellow berberine and the colorless hydrastine and canadine. IARC adds a group of flavonoids, including sideroxylin, and notes that the United States Pharmacopeia (USP) requires a dry goldenseal extract to contain at least 2% hydrastine and 2.5% berberine. Berberine is not unique to goldenseal. It also occurs in goldthread (Coptis), barberry and Oregon grape (Berberis), and other plants, and IARC records Coptis, Berberis, yellowroot (Xanthorhiza simplicissima), and Rumex species being used to adulterate goldenseal, because genuine root is expensive and some commercial products contain little or none of it. When Wallace and colleagues (Food and Chemical Toxicology 2018) analyzed 35 commercial goldenseal products, several turned out to come from another species or a mixture of plants. NCCIH likewise notes that some goldenseal products contain herbs not listed on the label. Because berberine occurs in so many plants, a yellow color or a berberine content figure alone does not prove that a product is goldenseal.

Goldenseal’s medical history begins with Indigenous nations of eastern North America. Ethnobotanical records compiled in a US Forest Service bibliography (Predny and Chamberlain 2005) describe Cherokee use of the root as a wash for inflammations and a treatment for indigestion, cancer, poor appetite, and general debility, and Cherokee people also mixed it with bear grease as an insect repellent. The same records list Iroquois uses for whooping cough, diarrhea, tuberculosis, liver disease, fever, earache, stomachache, flatulence, pneumonia, and heart trouble. King’s American Dispensatory (1898) adds that the yellow juice was used to color clothing and to stain the face, which explains names such as Indian paint and Indian dye. NCCIH summarizes Native American use for digestive disorders, wounds, skin and eye conditions, and cancer. European physicians learned of it through these traditions: King’s records that Benjamin Smith Barton, in his 1798 Collections for an Essay Toward a Materia Medica of the United States, mentioned the Cherokee use of the root against cancer, and later described it as a bitter tonic and a wash for inflamed eyes.

The root’s professional career came through the Eclectics, nineteenth-century American physicians who favored botanical medicines. According to King’s, goldenseal figured among their leading drugs from about 1847, and especially after John King’s American Dispensatory of 1852, in which King gave it a careful review while judging earlier claims to be greatly overdrawn. By the 1898 edition the Eclectics regarded it as specifically indicated for “catarrhal states of the mucous membranes”: chronic gastritis and indigestion, sore throat and nasal catarrh, and conjunctivitis, for which a colorless preparation was diluted 1 part in 10 or 20 of water. It was a favored local treatment for gonorrhea, and King’s describes it given by mouth and, heavily diluted, as a bladder wash for cystitis. Mainstream pharmacy adopted it too. A USP history by Brinckmann and colleagues (HerbalGram 2020) records goldenseal entering the US Pharmacopeia in 1860, leaving the USP in 1930 and the National Formulary in 1960, and returning to the USP in 2003. King’s adds that E. M. Hale introduced it into homeopathy.

Demand outran the plant early. King’s American Dispensatory (1898) observed that goldenseal disappeared as soon as settlers disturbed the ground, that once-plentiful stands along the Ohio River survived only in isolated spots, and that only Ohio, Indiana, Kentucky, and West Virginia still produced enough for commercial gathering. The Forest Service bibliography cites estimates of 140,000 to 150,000 pounds of root consumed a year in the late 1800s, prices rising from 8 to 12 cents a pound before 1880 to 58 cents by 1890, about 200,000 to 300,000 pounds a year by 1931, and more than 250,000 pounds around 2000; a pound of dried root takes roughly 200 to 250 rhizomes. Concern about supply prompted early cultivation manuals, including a 1908 US Department of Agriculture bulletin on growing goldenseal. The National Toxicology Program later chose goldenseal for long-term testing partly because it was one of the most widely used herbs in the United States.

Two modern episodes shaped how goldenseal is sold. The first is a myth: the idea that goldenseal can hide drugs on a urine test. The Forest Service bibliography traces it to John Uri Lloyd, a pharmacist and Eclectic author, and his 1900 novel Stringtown on the Pike, in which goldenseal in a dead man’s tonic is mistaken for strychnine by an expert witness, a false positive rather than a false negative. Laboratory studies have since failed to support the masking claim, but it persisted and added to demand. The second is conservation. On 18 September 1997, goldenseal was listed on Appendix II of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), which requires permits for international trade in its roots, and United Plant Savers keeps it on its At-Risk list of North American medicinal plants. In 2010 the National Toxicology Program published the two-year studies that led IARC to classify goldenseal root powder as possibly carcinogenic to humans.

Most proposed effects of goldenseal are attributed to its alkaloids, chiefly berberine and hydrastine (MSKCC). In laboratory studies berberine and goldenseal extracts are active against a range of bacteria, fungi, and parasites; MSKCC cites a comparison in which goldenseal extract was the most active of several herbs at inhibiting the stomach bacterium Helicobacter pylori. Laboratory work also shows that goldenseal relaxes smooth muscle like that of the gut, and that berberine stops cancer cells dividing in culture. None of these findings has been confirmed in clinical studies of goldenseal, and MSKCC states that clinical studies are lacking. Isolated berberine does have one well-known clinical effect in the gut. Rabbani and colleagues (Journal of Infectious Diseases 1987) found that it reduced the secretion of fluid into the intestine in diarrhea caused by toxin-producing E. coli, an effect that does not depend on absorbing the alkaloid into the blood. Laboratory studies cited by MSKCC also point to phototoxicity, which MSKCC suggests is more likely with preparations applied to the skin than with capsules.

Absorption is the central problem for any internal use. Berberine passes poorly from the gut into the blood: in rats, Chen and colleagues (AAPS PharmSciTech 2011) measured an absolute oral bioavailability of 0.68%, and NCCIH notes that very little berberine may be absorbed when people take goldenseal by mouth. Hydrastine behaves differently. Gupta and colleagues (Drug Metabolism and Disposition 2015) gave 11 healthy volunteers a single 2.7 g dose of goldenseal containing 78 mg of hydrastine and found it in the blood within about 1.5 hours, at a peak of 225 ng/ml, with a half-life of about 4.8 hours, followed by extensive breakdown into many metabolites. This matters for the most common questions about goldenseal. An antimicrobial that stays largely in the gut is unlikely to reach a throat infection, a sinus, or the bladder at useful concentrations, and whether swallowed goldenseal delivers enough berberine to the urine to affect bacteria has not been shown in people.

The best-characterized human effect of goldenseal is on drug-metabolizing enzymes. Both berberine and hydrastine are time-dependent inhibitors of CYP3A in laboratory tests, meaning they progressively disable the enzyme. Nguyen and colleagues (Journal of Pharmacology and Experimental Therapeutics 2023) gave healthy adults a single 3 g dose of goldenseal or 1 g three times a day for six days; either way, blood levels of midazolam, a sedative cleared by CYP3A, rose by 40 to 60%, and modeling pointed to hydrastine acting mainly on CYP3A in the gut wall. Goldenseal also inhibits CYP2D6 in people, and laboratory studies cited by MSKCC show inhibition of CYP2C9 and CYP3A5. Separately, goldenseal reduced the absorption of metformin from the gut without changing how fast the kidneys removed it. The toxicology has its own mechanism: berberine and its metabolite berberrubine inhibit topoisomerases, enzymes that manage DNA during cell division, which the National Toxicology Program and IARC suggest may explain the liver tumors in rodents, even though goldenseal powder and berberine were not mutagenic in standard bacterial tests.

Colds and immune support are the main modern uses. NCCIH lists goldenseal among supplements promoted for the common cold and other upper respiratory tract infections, and MSKCC notes that it is often combined with echinacea in products sold to support immune function; the Forest Service bibliography describes it as a so-called carrier herb used to boost other herbs, particularly echinacea. None of this has been tested properly. NCCIH states that there is not enough evidence to determine whether goldenseal is useful for any health condition and that no rigorous studies have evaluated it in people, and MSKCC finds no evidence for its use against the common cold. Most colds are caused by viruses, so laboratory activity against bacteria would not be expected to help them in any case. The combination with echinacea is a marketing tradition rather than a tested formula, and it brings goldenseal’s drug interactions along with it. Anyone who takes prescription medicines and wants an herbal cold product is better served by one without goldenseal.

Urinary tract infections are a frequent question, and the answer is short: there are no clinical trials of goldenseal for UTIs and no established dose. The idea has historical roots. King’s American Dispensatory (1898) described goldenseal given by mouth for cystitis and, heavily diluted, used to wash out the bladder, and Eclectic physicians used it locally for gonorrhea. Today’s reasoning relies on berberine’s antibacterial effect in the laboratory, but berberine is poorly absorbed, and no study has shown that goldenseal clears or prevents a bladder infection. A small 2021 case series by Pannek and Pannek-Rademacher (Spinal Cord Series and Cases) reported fewer catheter blockages in three of four people with spinal cord injury given homeopathic Hydrastis, a 30C dilution that contains essentially none of the plant; it says nothing about herbal goldenseal or infection. Because untreated bladder infections can spread to the kidneys, using goldenseal instead of testing and antibiotics risks delay. For preventing repeat infections, cranberry has the most research among herbs.

Digestive complaints were central to traditional use. King’s American Dispensatory recommended small doses of goldenseal as a bitter before meals for indigestion and chronic gastritis, and NCCIH notes that goldenseal is still promoted for diarrhea and constipation. The best human evidence comes from isolated berberine, not the herb. Rabbani and colleagues (Journal of Infectious Diseases 1987) tested berberine sulfate in randomized controlled trials involving 165 adults with acute diarrhea; in diarrhea caused by toxin-producing E. coli, a single 400 mg dose reduced stool volume, and 42% of treated patients had stopped having diarrhea at 24 hours compared with 20% of controls. In cholera the effect was slight and added nothing to the antibiotic tetracycline. That trial used a measured dose of a purified salt, and its results cannot be assumed for goldenseal capsules of unknown berberine content. Laboratory activity against H. pylori, the bacterium behind many stomach ulcers, has not been tested in people with goldenseal, and ulcers need proper diagnosis and treatment.

Eyes, mouth, and skin are the oldest local uses. Barton, writing from 1798 onward, described goldenseal as a wash for inflamed eyes, and King’s recommended a colorless goldenseal preparation diluted 1 part in 10 or 20 of water for conjunctivitis and inflamed eyelids, and as a local application for sore throats and ulcerated tonsils. The Forest Service bibliography notes that goldenseal was an ingredient of many commercial eyewashes until the 1980s, IARC notes berberine salts in some commercial eyewash formulations, and goldenseal itself appears in ear drops and feminine cleansing products. These uses have not been tested in modern trials. Home-made eye washes from powdered root or tea are not sterile and can introduce infection, and a red, painful eye, especially with blurred vision or sensitivity to light, needs an eye examination rather than an herbal rinse. MSKCC adds that laboratory studies point to possible sun sensitivity with goldenseal applied to the skin.

Blood sugar, cholesterol, and weight belong to berberine, not goldenseal. NCCIH explains that berberine has been studied for its effects on blood sugar, cholesterol levels, body weight, and other outcomes, but that study results on berberine may not apply to goldenseal because so little berberine is absorbed from the root. Whole goldenseal has not been tested as a diabetes treatment. In a pharmacology study of adults with type 2 diabetes already taking metformin, Nguyen and colleagues (Clinical and Translational Science 2025) recorded HbA1c falling on average from 6.8% to 6.5% over the study period whether or not goldenseal had lowered metformin levels; the study was designed to measure drug levels, not to test goldenseal as a treatment. Finally, two popular uses are simply myths: goldenseal is not a reliable way to mask drug use on a urine test, and it is not an antibiotic substitute for strep throat, pneumonia, Lyme disease, or any diagnosed infection.

Goldenseal is sold as dried, cut, or powdered rhizome and root, capsules, tablets, tinctures and liquid extracts, teas, and combination products, especially with echinacea; IARC also lists ear drops, cold and flu remedies, allergy products, laxatives, and digestive aids containing it. There is no established clinical dose for any condition. NCCIH reports that small research studies have given about 3 g a day for short periods without serious harm, and the drug interaction studies used similar amounts: 3,210 mg a day for 14 days in Gurley and colleagues’ digoxin study, and either a single 3 g dose or 1 g three times a day for six days in Nguyen and colleagues’ midazolam study. King’s American Dispensatory (1898) gave doses of 10 to 30 grains of powdered root, roughly 0.65 to 2 g, and 10 to 60 minims of fluid extract. Those figures describe what has been used, not what has been shown to work. Interaction studies found measurable effects within days, so even a short course can affect medicines.

Quality varies widely. The USP standard for dry goldenseal extract requires at least 2% hydrastine and 2.5% berberine, which gives buyers a benchmark to look for on the label. Because genuine goldenseal is expensive, IARC reports products containing little or no goldenseal, and substitution with cheaper berberine plants such as Coptis, Berberis, and yellowroot. In the Wallace analysis of 35 commercial products, several were identified as another species or a mixture, and NCCIH notes products with herbs not listed on the label. A yellow color and a bitter taste are not proof of identity. Products that name Hydrastis canadensis root and rhizome, state their hydrastine and berberine content, and carry an independent quality seal are more likely to contain what the label says, though a seal is not a guarantee of safety or benefit. Taste is a useful warning in its own right: King’s describes the root as intensely bitter with a lingering acridity, which capsules hide.

Sourcing matters because wild goldenseal is under pressure. NCCIH notes that wild goldenseal has been overharvested and that the plant is grown commercially but is expensive to cultivate. The Forest Service bibliography explains why: plants take three to five years to reach harvest from rhizome divisions and five to seven years from seed, need 60 to 75% shade, and suffer from slugs, nematodes, and fungal diseases; an industry survey counted only 140 acres under cultivation in 1998. United Plant Savers recommends using At-Risk plants such as goldenseal in cultivated forms whenever possible and keeping any wild harvest very limited. CITES controls international trade in whole, cut, and powdered roots, but its annotation for goldenseal excludes finished products such as capsules, tinctures, and ointments, so a CITES listing does not tell you whether the root in a bottle was farmed or dug. Ask suppliers whether their root is cultivated, and treat “wildcrafted” on a goldenseal label as a conservation question rather than a mark of quality.